Biophytis SA has announced that it will hold its Ordinary and Extraordinary General Meeting on November 12, 2026. This meeting is significant as it will address key developments regarding the company’s lead drug candidate, BIO101, and its strategic direction in the pharmaceutical industry.
Scheduled for 2:00 p.m. at the Silver Innov Building in Ivry-sur-Seine, the meeting will involve discussions on various resolutions that are crucial for the company’s future. The announcements come at a pivotal time for Biophytis, as it has recently achieved several milestones in the development of BIO101, which targets obesity and sarcopenia.
Background
Biophytis SA is a company focused on pharmaceutical preparations, as indicated by its SIC code 2834. The company is classified as a non-accelerated filer and an emerging growth company. Its recent filings include various forms, with the latest being a 6-K filed on October 23, 2026, which outlines the details of the upcoming general meeting.
What the Filing Says
The recent filing states, "Biophytis’ Ordinary and Extraordinary General Meeting will be held on November 12, 2026." This meeting will provide shareholders with the opportunity to review the general report of the Board of Directors, statutory auditors’ reports, and proposed resolutions.
Impact
The upcoming general meeting may significantly impact shareholders and stakeholders in the pharmaceutical industry. The resolutions to be discussed are aimed at ensuring Biophytis has the necessary resources to continue its development strategy, particularly for BIO101.
What's Next
Shareholders are encouraged to participate in the voting process for the proposed resolutions. The filing does not specify what happens next beyond the meeting.